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Abstract Preproadrenomedullin, the precursor of proadreno-
medullin N-terminal 20 peptide (PAMP), is produced by rat zona
glomerulosa cells. The actions of PAMP on the rat adrenal have
been investigated. PAMP was found to stimulate aldosterone
secretion and cAMP release by intact capsules, in a dose-
dependent manner, but had only a minor effect on dispersed cells.
The effects of PAMP on aldosterone secretion were inhibited by
HA1004, an inhibitor of protein kinase A. The difference
between tissue preparations does not appear to be due to the
actions of PAMP on local release of catecholamines as PAMP
inhibited the release of catecholamines from rat capsular
preparations. These data suggest that PAMP is a novel zona
glomerulosa stimulant in intact capsular tissue, acting through
cAMP.
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1. Introduction
Proadrenomedullin N-terminal 20 peptide (PAMP) is a re-
cently identi¢ed cleavage product of preproadrenomedullin,
which is expressed in a wide range of di¡erent human tissues
[1]. We have recently demonstrated that the gene encoding
preproadrenomedullin is expressed in the rat adrenal zona
glomerulosa [2]. Speci¢c binding sites for PAMP have been
identi¢ed in many di¡erent tissues in the rat, including the
adrenal glands [3]. More recently speci¢c PAMP receptors
have been identi¢ed in the rat adrenal zona glomerulosa,
and there is evidence that activation of the PAMP receptor
leads to an increase in cAMP production in this tissue [4].
This is consistent with ¢ndings in other tissues, such as the
cat mesenteric vascular bed, in which the e¡ect of PAMP is
mediated by cAMP [5]. In the light of these observations it
may be hypothesised that PAMP is a stimulus to aldosterone
secretion, in common with other agents which elevate cAMP
levels in the zona glomerulosa. However, the one group which
has, to date, studied the actions of PAMP on the rat zona
glomerulosa suggests that this peptide inhibits aldosterone
secretion [6,7].
The present study was designed to further investigate the
actions of PAMP on cAMP and aldosterone secretion by the
rat adrenal zona glomerulosa. The intact capsular preparation
was chosen because this tissue preparation retains some of the
architecture of the gland, and is likely to be more relevant to
the in vivo situation than a dispersed cell preparation. In
particular, previous studies from our laboratory and others
have suggested that, in the rat adrenal zona glomerulosa,
peptide-stimulated local release of catecholamines from islets
of chroma⁄n cells located within the zona glomerulosa may
have a role in intraglandular signal transduction and may also
account for di¡erences in responses seen between di¡erent
tissue preparations [8]. This possibility was also addressed
by the present studies by investigating the e¡ects of PAMP
on capsular catecholamine release.
2. Materials and methods
All chemicals were obtained from Sigma Chemical Co. (Poole, Dor-
set, UK) or BDH (Poole, Dorset, UK), with the following exceptions:
proadrenomedullin N-terminal 20-peptide (PAMP), [125I]PAMP and
rat adrenomedullin were obtained from Phoenix Pharmaceuticals
(Mountain View, CA, USA), and HA1004 was bought from Semat
Laboratories (St Albans, Herts., UK). ACTH1-24 (Synacthen) was
obtained from Ciba-Geigy (Horsman, Surrey, UK).
Female Wistar rats (body weight 250^350 g) were obtained from the
colony at Queen Mary and West¢eld College, and maintained on a
normal rat diet with food and tap water available ad libitum. Animals
were rapidly killed by mechanical stunning followed by cervical dis-
location. Adrenal glands were excised and glomerulosa tissue sepa-
rated from inner zones and medulla by gentle compression between
glass plates. Adrenal capsules were prepared and incubated in Krebs
bicarbonate Ringer as previously described [9] in the presence or
absence of stimulants. At the end of the incubation period tissues
were removed from the medium, which was then stored frozen at
320‡C until assayed for aldosterone and cAMP.
Zona glomerulosa and zona fasciculata/reticularis cell suspensions
were prepared by collagenase digestion and mechanical dispersal as
previously described [10]. Zona glomerulosa cells and inner zone
(zona fasciculata/reticularis) cells were separately incubated in Krebs
bicarbonate Ringer containing 2 mg glucose/ml and 2 mg bovine
serum albumin (fraction V)/ml. Cells were incubated in Eppendorf
tubes at a density of 10 000/ml in an incubation volume of 1 ml, under
an atmosphere of 95% O2/5% CO2 at 37‡C for 60 min. Peptide addi-
tives were dissolved in incubation medium and added as required. At
the end of the incubation cells were pelleted by centrifugation, me-
dium removed and stored at 320‡C.
Aliquots of incubation medium were assayed for aldosterone (zona
glomerulosa cells and capsules) and corticosterone (inner zone cells)
by radioimmunoassay as previously described [10]. cAMP was meas-
ured by competitive protein binding assay as previously described [10].
All experiments were carried out in duplicate and repeated at least
three times.
The role of cAMP-dependent mechanisms in the action of PAMP
on the zona glomerulosa was investigated using HA1004 (Semat Tech-
nical, St Albans, Herts., UK), a selective inhibitor of protein kinase A
at the concentration used (1 Wmol/l) [11]. Adrenal capsules were in-
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cubated as described above, with 100 nmol/l PAMP, in the presence
and absence of HA1004 (1 Wmol/l).
Catecholamine release was measured by assaying the total adrena-
line and noradrenaline content of incubation medium from intact
capsules using a £uorescent method as previously described [2].
Dose response data were analysed using analysis of variance (AN-
OVA). For other data the Student’s t-test was used.
3. Results
PAMP caused a dose-dependent increase in aldosterone se-
cretion by intact rat adrenal capsular tissue incubated in vitro
(Fig. 1). The minimum concentration of PAMP required for
signi¢cant stimulation of aldosterone secretion was found to
be 10 nmol/l. The maximal e¡ect of PAMP was seen at a
concentration of 1 Wmol/l (the highest concentration tested).
At this concentration PAMP caused a four-fold increase in
aldosterone secretion compared with basal levels. PAMP also
caused a signi¢cant increase in cAMP release from rat adrenal
capsular tissue (Fig. 1). The minimum concentration of
PAMP required for this action was 10 nmol/l. The maximal
increment in cAMP was a twofold increase over basal. The
e¡ects of PAMP on aldosterone secretion by intact capsular
tissue were signi¢cantly attenuated in the presence of 1 Wmol/l
HA1004, a protein kinase A inhibitor. This inhibitor also
signi¢cantly attenuated the aldosterone response to ACTH
stimulation (Fig. 2).
In dispersed zona glomerulosa cells, however, PAMP only
had a very small e¡ect on basal aldosterone secretion (Fig. 3),
although a highly signi¢cant dose-dependent increase in
cAMP release was observed (Fig. 3). At a concentration of
1 Wmol/l PAMP caused a 50% increase in aldosterone secre-
tion over basal levels, while there was a fourfold increase in
cAMP secretion. PAMP did not a¡ect corticosterone secretion
by zona fasciculata/reticularis cells at any concentration used
(data not shown).
PAMP at a concentration of 100 nmol/l was found to cause
a signi¢cant decrease in the release of catecholamines from
adrenal capsular tissue (Fig. 4).
4. Discussion
The data obtained in the present study suggest that PAMP
acts on the intact rat adrenal zona glomerulosa to stimulate
aldosterone secretion. These data, showing an increase in
cAMP production in response to PAMP, together with inhib-
ition of the response in the presence of a speci¢c PKA antag-
onist suggest that the adrenocortical response to PAMP is
mediated by cAMP as second messenger. This is in accord-
ance with our previous studies demonstrating the presence of
speci¢c PAMP receptors linked to adenylyl cyclase in the rat
zona glomerulosa [4]. It is not clear, however, why dispersed
cells do not respond in the same way to PAMP stimulation.
The apparent paradox presented by the observation of a four-
fold increase in cAMP release with less than a twofold change
in aldosterone secretion may be explained if PAMP were act-
ing on one of the other cell types known to be present in this
preparation: vascular endothelial cells for example. The
cAMP released from such cells would not be available to
the zona glomerulosa cells owing to the poor ability of
cAMP to penetrate cells.
Previous studies of the e¡ects of PAMP on aldosterone
secretion from Nussdorfer’s group also found that PAMP
had no e¡ect on basal aldosterone secretion by dispersed
zona glomerulosa cells, although they reported an inhibitory
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Fig. 1. E¡ects of PAMP on aldosterone secretion (square symbols)
and cAMP release (round symbols) by intact rat adrenal capsular
tissue incubated in vitro. Data are means þ S.E.M., n = 6. *P6 0.05,
**P6 0.01, ***P6 0.001 compared to basal values (ANOVA).
Fig. 2. E¡ects of PAMP on aldosterone secretion (square symbols)
and cAMP release (round symbols) by collagenase-dispersed rat
adrenal zona glomerulosa cells incubated in vitro. Data are means
þ S.E.M., n = 6. *P6 0.05, **P6 0.01, ***P6 0.001 compared to
basal values (ANOVA).
Fig. 3. E¡ects of the protein kinase A inhibitor HA1004 (1 Wmol/l)
on the aldosterone response to PAMP (100 nmol/l) and ACTH (1
nmol/l) in intact capsular tissue. Open bars show response in the ab-
sence of HA1004, hatched bars show response in the presence of
HA1004. Data are means þ S.E.M., n = 6. ***P6 0.001 compared to
response in the absence of HA1004 (Student’s t-test).
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e¡ect of PAMP on angiotensin II-stimulated aldosterone se-
cretion [6,7]. The discrepancy between these two tissue prep-
arations is similar to the e¡ects of vasoactive intestinal poly-
peptide (VIP), which has no e¡ect on basal aldosterone
secretion by dispersed cells, but stimulates intact tissue [8].
Adrenomedullin has also been reported to exert opposite ef-
fects on dispersed cells and intact capsular tissue, like PAMP,
causing stimulation of aldosterone in capsules [9] or other
intact adrenal preparations [12] while inhibiting aldosterone
secretion by cells [6,7,13,14], although it should be noted that
the actions of adrenomedullin on dispersed cells also appear
to depend on the receptor subtype which predominates in the
population of animals used [2]. It is entirely possible that
inherent di¡erences in the rat populations used for these ex-
periments may account for the di¡erences seen. It appears to
be a possibility that part of the e¡ect of PAMP is mediated by
the adrenomedullin receptor, as PAMP and adrenomedullin
share a common binding site [4]. This is a major di¡erence
between the populations of rats used by our group, which
expresses a speci¢c adrenomedullin receptor [2], and the ani-
mals used by Nussdorfer’s group, in which all the actions of
adrenomedullin are mediated by the CGRP receptor [13].
There remains, however, the question as to why PAMP is a
potent stimulus to aldosterone secretion in intact capsular
tissue but not in dispersed cells. An explanation which has
been o¡ered for the di¡ering e¡ects of a peptide on intact
tissue and dispersed cells is the existence of intraglandular
signal transduction mechanisms. These include the local re-
lease of catecholamines from either nerves within the adrenal
capsule/zona glomerulosa or from islets of chroma⁄n cells in
the capsular region [8,15]. The possibility that PAMP may act
in this manner was investigated by measuring catecholamine
release by intact capsular tissue in response to PAMP. As
PAMP was shown to cause a decrease in the release of cat-
echolamines it is most unlikely that this mechanism may ex-
plain the di¡erence in the response of the tissue preparations.
The e¡ect of PAMP on catecholamine secretion is consistent
with a previous report of PAMP inhibition of catecholamine
secretion by cultured bovine chroma⁄n cells [16].
In conclusion, it appears that PAMP is stimulatory to al-
dosterone secretion in intact tissue preparations, and this ef-
fect is mediated by cAMP. It is not clear why PAMP does not
stimulate dispersed cell preparations, but this discrepancy may
suggest the existence of as yet uncharacterised intraglandular
signal transduction mechanisms.
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Fig. 4. E¡ects of PAMP (100 nmol/l) on the release of catechol-
amines from rat adrenal capsular tissue incubated in vitro. Data are
means þ S.E.M., n = 6. **P6 0.01 compared to control (basal) levels
(ANOVA).
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